The Exactech knee replacement lawsuit involves thousands of patients who received defective knee implants with faulty polyethylene components that degraded prematurely due to defective packaging. As of January 2026, more than 2,500 people have filed claims against Exactech, with 1,838 cases consolidated in federal multidistrict litigation and over 700 cases in Florida state court. The root cause of the failures traces to packaging bags that lacked a proper oxygen barrier layer, causing the polyethylene inserts to oxidize and break down far sooner than expected””leading to pain, instability, bone loss, and the need for revision surgery. For example, a patient who received an OPTETRAK knee replacement in 2015 might have expected their implant to last 15-20 years but instead experienced failure within 5-7 years due to the degraded components.
This litigation has taken a significant turn with Exactech filing for Chapter 11 bankruptcy in October 2024, temporarily halting all lawsuits. Lawyers estimate potential individual settlements could range between $100,000 and $300,000 per case, though no individual settlements have been approved yet. The company has already paid $8 million to resolve False Claims Act allegations that it knowingly sold defective implants to government healthcare programs. This article covers the scope of the recall, the current litigation status, what the bankruptcy means for claimants, and the steps affected patients should consider taking.
Table of Contents
- What Caused the Exactech Knee Replacement Recall?
- Current Status of the Exactech MDL Litigation
- What the Government Settlement Reveals About Exactech’s Knowledge
- How Exactech’s Bankruptcy Affects Your Lawsuit
- Symptoms and Complications That May Support a Claim
- Estimated Settlement Values and Recovery Timelines
- What Happens Next in the Exactech Litigation
- Conclusion
What Caused the Exactech Knee Replacement Recall?
The Exactech recall stems from a fundamental manufacturing defect: the packaging bags used to store polyethylene knee insert components were missing an oxygen barrier layer. Polyethylene, the plastic material used in the bearing surfaces of knee replacements, is highly susceptible to oxidation. When exposed to oxygen over time””whether during storage before implantation or after being placed in a patient’s body””the material degrades, becomes brittle, and breaks down. The FDA classified this as a Class II recall in July 2021, and Exactech expanded the voluntary recall on February 7, 2022, to include all Optetrak, Logic, and Truliant knee replacements. The numbers are substantial.
Approximately 143,484 knee inserts produced with non-conforming packaging were implanted in the United States since 2004. This includes over 60,000 OPTETRAK units, over 60,000 OPTETRAK Logic units, approximately 25,000 TRULIANT inserts, and around 1,500 VANTAGE Fixed-Bearing Liner components. When combined with hip, ankle, and shoulder devices affected by the same packaging issue, the total reaches approximately 657,391 devices. The comparison to other medical device recalls is instructive. Unlike recalls where a specific manufacturing batch was defective, the Exactech recall affects nearly two decades of production””any patient who received one of these knee implants dating back to 2004 could potentially be affected. This extended timeframe means many patients have already experienced implant failure, while others may face future complications as their devices continue to degrade.
Current Status of the Exactech MDL Litigation
The federal litigation is consolidated as mdl 3044 in the U.S. District Court for the Eastern District of New York, presided over by Judge Nicholas G. Garaufis. As of January 2026, 1,838 cases are pending in this multidistrict litigation. Additionally, over 700 cases are proceeding in consolidated Florida state court proceedings, reflecting Exactech’s headquarters location in Gainesville, Florida. However, the litigation timeline has been significantly disrupted by Exactech’s bankruptcy filing.
All lawsuits were temporarily halted when the company filed for Chapter 11 protection on October 29, 2024. This automatic stay prevents plaintiffs from pursuing their cases in civil court while the bankruptcy proceeds. Jury selection had potentially been scheduled to begin in January 2026, but the bankruptcy has thrown that timeline into question. The litigation trust created through the bankruptcy plan may offer an alternative path for claimants. This trust is designed to pursue claims against TPG, the private equity sponsor that owned Exactech, on behalf of tort claimants and unsecured creditors. TPG has already agreed to a $10 million settlement in March 2025, though this represents a fraction of the potential damages across thousands of claims.
What the Government Settlement Reveals About Exactech’s Knowledge
The $8 million settlement Exactech paid to resolve False Claims Act allegations provides a window into what the company allegedly knew and when. According to these allegations, Exactech first learned in 2006 that some components had high failure rates. By 2008, the company allegedly knew of problems with the finned tibial tray””yet continued selling that component through 2018, a full decade later. In 2019, the company allegedly became aware that polyethylene components in certain Logic and Truliant systems were failing prematurely.
These allegations matter for individual lawsuits because they speak to whether Exactech acted with knowledge of the defects. A company that unknowingly sells a defective product faces different legal exposure than one that allegedly continued sales despite internal knowledge of problems. The False Claims Act settlement specifically addressed sales to Medicare, Medicaid, and VA programs, meaning the government concluded that Exactech knowingly submitted claims for payment on devices it had reason to believe were defective. For patients building their individual cases, this timeline is significant. Someone who received an Exactech knee replacement in 2018 could potentially argue that the company had over a decade of internal knowledge about component failures before their surgery.
How Exactech’s Bankruptcy Affects Your Lawsuit
Exactech’s Chapter 11 bankruptcy filing on October 29, 2024, fundamentally changed the landscape for claimants. An investor group of private equity and alternative asset firms is providing approximately $85 million in financing to keep the company operational during bankruptcy proceedings. The automatic stay that accompanies Chapter 11 filings means individual lawsuits cannot proceed until the bankruptcy court permits them to continue or the company emerges from bankruptcy. The tradeoff for claimants is significant. On one hand, the bankruptcy process may ultimately provide a structured mechanism for resolving claims, potentially through the litigation trust established in the bankruptcy plan.
This trust specifically targets TPG, the private equity sponsor, preserving the ability to seek recovery from parties beyond just Exactech itself. On the other hand, bankruptcy often means reduced recoveries for claimants, as they become unsecured creditors competing with other company obligations. Claimants should understand that the $85 million in financing is primarily intended to keep Exactech’s business operations running””not to pay tort claims. The litigation trust and any eventual bankruptcy settlement will determine what funds are actually available for injured patients. Legal counsel familiar with both medical device litigation and bankruptcy proceedings is essential for navigating this dual-track process.
Symptoms and Complications That May Support a Claim
Patients with Exactech knee implants should monitor for specific symptoms that may indicate device failure due to polyethylene degradation. These include persistent or worsening knee pain, swelling that doesn’t resolve, instability or a feeling that the knee might give way, clicking or grinding sensations, reduced range of motion, and difficulty walking or bearing weight. The degraded polyethylene can produce wear debris that triggers inflammatory reactions, leading to bone loss around the implant””a condition called osteolysis. A critical warning: not all patients with Exactech implants will experience problems, and symptoms can have other causes. Knee replacement patients may experience some ongoing discomfort or limitations unrelated to the recall.
The key indicator is often a change from baseline””a knee that functioned well for several years but has begun deteriorating. Documentation of this timeline through medical records is essential for supporting a legal claim. Patients who have already undergone revision surgery to replace a failed Exactech implant have the clearest path to demonstrating injury. However, those currently experiencing symptoms should consult with their orthopedic surgeon for evaluation. Medical documentation of device failure, particularly pathology reports confirming polyethylene degradation, provides the strongest foundation for litigation.
Estimated Settlement Values and Recovery Timelines
Lawyers handling Exactech cases estimate potential individual settlements could range between $100,000 and $300,000 per case. This range accounts for variations in injury severity, medical expenses, revision surgery costs, lost wages, and pain and suffering. A patient who required revision surgery, experienced complications, and faces ongoing limitations would likely fall toward the higher end of this range.
These estimates come with important caveats. No individual settlements have been approved in MDL 3044 as of January 2026, meaning no actual settlement amounts have been established through litigation. The $8 million government settlement and $10 million TPG settlement provide some reference points, but these addressed specific legal claims rather than individual patient injuries. The bankruptcy adds further uncertainty””the ultimate recovery for claimants will depend on how the bankruptcy proceedings resolve and what assets remain available for tort claims.
What Happens Next in the Exactech Litigation
The immediate future of the Exactech litigation hinges on the bankruptcy proceedings in Delaware. Once the company either emerges from Chapter 11 or the court modifies the automatic stay to permit litigation to continue, the MDL cases before Judge Garaufis can resume. The litigation trust’s pursuit of claims against TPG may proceed on a separate track, potentially providing an alternative recovery path for claimants.
Patients who believe they have claims should not wait for the bankruptcy to resolve before consulting with an attorney. Statutes of limitations continue to run in most circumstances, and preserving evidence””including medical records, pathology reports from any removed devices, and documentation of expenses and impacts””should happen now. The complexity of pursuing claims during bankruptcy makes early legal consultation particularly important for Exactech patients.
Conclusion
The Exactech knee replacement lawsuit represents one of the larger medical device litigations in recent years, with over 2,500 claimants seeking compensation for injuries caused by faulty polyethylene components. The defective packaging that caused premature device degradation affected knee implants going back to 2004, and allegations that the company knew of problems for years before the recall add weight to plaintiffs’ claims. The $8 million False Claims Act settlement and internal knowledge timeline suggest Exactech may face significant liability.
The bankruptcy filing complicates the path to recovery but does not eliminate it. Patients with Exactech knee implants who have experienced device failure, required revision surgery, or are suffering ongoing symptoms should gather their medical records, consult with an attorney experienced in medical device litigation, and monitor developments in both the MDL and bankruptcy proceedings. While the estimated settlement range of $100,000 to $300,000 per case remains theoretical until actual settlements are approved, the scale of the recall and the evidence of corporate knowledge provide a substantial foundation for claims.